PAVM vs. PETV, SSKN, BTCY, NXGL, TTOO, MHUA, MBOT, AKLI, OSA, and NEPH
Should you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include PetVivo (PETV), STRATA Skin Sciences (SSKN), Biotricity (BTCY), NEXGEL (NXGL), T2 Biosystems (TTOO), Meihua International Medical Technologies (MHUA), Microbot Medical (MBOT), Akili (AKLI), ProSomnus (OSA), and Nephros (NEPH). These companies are all part of the "surgical & medical instruments" industry.
PAVmed (NASDAQ:PAVM) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk.
19.9% of PAVmed shares are owned by institutional investors. Comparatively, 24.6% of PetVivo shares are owned by institutional investors. 12.6% of PAVmed shares are owned by company insiders. Comparatively, 20.1% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, PAVmed had 7 more articles in the media than PetVivo. MarketBeat recorded 8 mentions for PAVmed and 1 mentions for PetVivo. PetVivo's average media sentiment score of 1.87 beat PAVmed's score of 0.21 indicating that PetVivo is being referred to more favorably in the news media.
PetVivo has a net margin of -1,016.64% compared to PAVmed's net margin of -4,660.07%. PAVmed's return on equity of -532.56% beat PetVivo's return on equity.
PetVivo has higher revenue and earnings than PAVmed. PetVivo is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
PAVmed received 200 more outperform votes than PetVivo when rated by MarketBeat users.
PAVmed has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, PetVivo has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.
PAVmed presently has a consensus price target of $21.00, suggesting a potential upside of 669.23%. Given PAVmed's higher possible upside, equities analysts clearly believe PAVmed is more favorable than PetVivo.
Summary
PetVivo beats PAVmed on 8 of the 15 factors compared between the two stocks.
Get PAVmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools